Forced degradation of fentanyl: Identification and analysis of impurities and degradants

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 3, 2010, Pages 325-334

  Garg, Anuradha ^a   Solas, Dennis W ^a   Takahashi, Lori H ^a   Cassella, James V ^a  

^a Alexza Pharmaceuticals   (United States)

Author keywords

Degradants; Fentanyl; Forced degradation; Impurities; Structural alerts; Validation

Indexed keywords

1 PHENETHYL 1H PYRIDIN 2 ONE; 1 PHENETHYLPYRIDINIUM SALT; 1 STYRYL 1H PYRIDIN 2 ONE; ACETYL FENTANYL; BUTYRYL FENTANYL; CHEMICAL COMPOUND; FENTANYL; FENTANYL DERIVATIVE; HYDROGEN PEROXIDE; N PHENYL 1 (2 PHENYLETHYL)PIPERIDIN 4 AMINE; NITROGEN; NORFENTANYL; PIPERIDINE; PROPIONANILIDE; PYRUVYL FENTANYL; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; LIGHT; LIGHT EXPOSURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; NUCLEAR OVERHAUSER EFFECT; OXIDATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

DRUG CONTAMINATION; DRUG STABILITY; FENTANYL; LIMIT OF DETECTION; OXIDATION-REDUCTION; PHOTOLYSIS;

EID: 77954862955     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.04.004     Document Type: Article

References (12)

1. Rabinowitz J.D., Wensley M., Lloyd P., Myers D., Shen W., Lu A., Hodges C., Hale R., Mufson D., Zaffaroni A. Fast Onset Medications through Thermally Generated Aerosols. J. of Pharmacol. Exp. Ther. 2004, 309:769-775.
2. Lambropoulos J., Spanos G.A., Lazaridis N., Ingallinera T.S., Rodriguez V.K. Development and Validation of an HPLC Assay for Fentanyl and Related Substances in Fentanyl Citrate Injection, USP. J. Pharm. Biomed. Anal. 1999, 20:705-716.
3. Chen J., Lin H., Gao H., Bolton K., Zhang J. Formation kinetics of potentially genotoxic degradant of fentanyl in hydrogel matrix. Poster Presentation at 2006 AAPS Annual Meeting and Exposition 2006.
4. Fentanyl Monograph 2005, European Pharmacopoeia, pp. 1584-1585. fifth ed.
5. EU EMEA/CHMP, Guideline on the Limits of Genotoxic Impurities, January (2007). Available from: http://www.emea.europa.eu/pdfs/human/swp/519902en.pdf.
6. US FDA/CDER, Guidance for Industry (Draft). Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches (2008). Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079235.pdf.
7. Bhattacharya L., Pappa H., Russo K., Sheinin E., William R. The Use of Relative Response Factors to Determine Impurities. Pharm. Forum. 2005, 31:960-966.
8. Nishikawa R.K., Bell S.C., Kraner J.C., Callery P.S. Potential Biomarkers of Smoked Fentanyl Utilizing Pyrolysis Gas Chromatography-Mass Spectrometry. J. Anal. Toxicol. 2009, 33:418-422.
9. March J. Advanced Organic Chemistry 1977, McGraw Hill, pp. 895-922. second ed.
10. Bailey A.B., Chanderbhan R., Collazo-Braier N., Cheeseman M.A., Twaroski M.L. The use of structure-activity relationship analysis in the food contact notification program. Regul. Toxicol. Pharmacol. 2005, 42:225-235.
11. Benigni R., Bossa C. Structure alerts for carcinogenicity, and the Salmonella assay system: A novel insight through the chemical relational databases technology. Mutat. Res. 2008, 659:248-261.
12. Matthews E.J., Kruhlak N.L., Benz R.D., Contrera J.F., Merchant C.A., Yang C. Combined use of MC4PC, MDL-QSAR, BioEpistreme, Leadscope PDM, and Derek for windows software to achieve high-performance, high-confidence, mode of action-based predictions of chemical carcinogenesis. Toxicol. Mech. Methods 2008, 18:189-206.